{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T12:46:34Z","timestamp":1772196394607,"version":"3.50.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2010,2]]},"DOI":"10.1016\/j.vaccine.2009.10.094","type":"journal-article","created":{"date-parts":[[2010,2,26]],"date-time":"2010-02-26T10:27:47Z","timestamp":1267180067000},"page":"1919-1923","source":"Crossref","is-referenced-by-count":31,"title":["Immunostimulatory CpG oligonucleotides: Effect on gene expression and utility as vaccine adjuvants"],"prefix":"10.1016","volume":"28","author":[{"given":"Dennis M.","family":"Klinman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sven","family":"Klaschik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Tomaru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidekazu","family":"Shirota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debra","family":"Tross","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidekazu","family":"Ikeuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2009.10.094_bib1","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1189\/jlb.71.5.813","article-title":"Differential and competitive activation of human immune cells by distinct classes of CpG oligodeoxynucleotides","volume":"71","author":"Gursel","year":"2002","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.vaccine.2009.10.094_bib2","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/35047123","article-title":"A toll-like receptor recognizes bacterial DNA","volume":"408","author":"Hemmi","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2009.10.094_bib3","doi-asserted-by":"crossref","first-page":"4531","DOI":"10.4049\/jimmunol.168.9.4531","article-title":"Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides","volume":"168","author":"Hornung","year":"2002","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2009.10.094_bib4","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1073\/pnas.93.7.2879","article-title":"CpG motifs expressed by bacterial DNA rapidly induce lymphocytes to secrete IL-6, IL-12 and IFNg","volume":"93","author":"Klinman","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2009.10.094_bib5","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.4049\/jimmunol.167.7.3555","article-title":"Cutting Edge: role of toll-like receptor 9 in CpG DNA-induced activation of human cells","volume":"167","author":"Takeshita","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2009.10.094_bib6","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.157.5.1840","article-title":"Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA","volume":"157","author":"Ballas","year":"1996","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2009.10.094_bib7","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1006\/cimm.1996.0009","article-title":"Bacterial DNA induces murine interferon-gamma production by stimulation of IL-12 and tumor necrosis factor-alpha","volume":"167","author":"Halpern","year":"1996","journal-title":"Cell Immunol"},{"key":"10.1016\/j.vaccine.2009.10.094_bib8","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1084\/jem.20020773","article-title":"Potential role of phosphatidylinositol 3 kinase, rather than DNA-dependent protein kinase, in CpG DNA-induced immune activation","volume":"196","author":"Ishii","year":"2002","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2009.10.094_bib9","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/374546a0","article-title":"CpG motifs in bacterial DNA trigger direct B-cell activation","volume":"374","author":"Krieg","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2009.10.094_bib10","doi-asserted-by":"crossref","first-page":"5000","DOI":"10.4049\/jimmunol.166.8.5000","article-title":"Bacterial CpG DNA triggers activation and maturation of human CD11c(\u2212), CD123(+) dendritic cells","volume":"166","author":"Bauer","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2009.10.094_bib11","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1084\/jem.194.6.863","article-title":"Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens","volume":"194","author":"Kadowaki","year":"2001","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2009.10.094_bib12","doi-asserted-by":"crossref","first-page":"3026","DOI":"10.1002\/1521-4141(2001010)31:10<3026::AID-IMMU3026>3.0.CO;2-H","article-title":"Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12","volume":"31","author":"Krug","year":"2001","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.vaccine.2009.10.094_bib13","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/S0264-410X(01)00387-5","article-title":"Anthrax vaccine: short-term safety experience in humans","volume":"20","author":"Pittman","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2009.10.094_bib14","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1038\/nm1201-1271","article-title":"Bioterrorism: a clear and present danger","volume":"7","author":"Lane","year":"2001","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2009.10.094_bib15","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S0022-2143(96)90035-9","article-title":"Amplification of antibody production by phosphorothioate oligodeoxynucleotides","volume":"128","author":"Branda","year":"1996","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.vaccine.2009.10.094_bib16","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/S0264-410X(98)80122-9","article-title":"CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus","volume":"16","author":"Moldoveanu","year":"1998","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2009.10.094_bib17","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1016\/j.micinf.2007.08.002","article-title":"Systemic but not mucosal immunity induced by AVA prevents inhalational anthrax","volume":"9","author":"Klinman","year":"2007","journal-title":"Microb Infect"},{"key":"10.1016\/j.vaccine.2009.10.094_bib18","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1196\/annals.1348.030","article-title":"CpG oligonucleotides improve the protective immune response induced by the licensed anthrax vaccine","volume":"1082","author":"Klinman","year":"2006","journal-title":"Ann NY Acad Sci"},{"key":"10.1016\/j.vaccine.2009.10.094_bib19","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1128\/IAI.73.2.828-833.2005","article-title":"CpG oligodeoxynucleotides adsorbed onto polylactide-co-glycolide microparticles improve the immunogenicity and protective activity of the licensed anthrax vaccine","volume":"73","author":"Xie","year":"2005","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2009.10.094_bib20","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1016\/j.vaccine.2003.12.020","article-title":"CpG oligonucleotides improve the protective immune response induced by the anthrax vaccination of rhesus macaques","volume":"22","author":"Klinman","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2009.10.094_bib21","unstructured":"Rynkiewicz, D., Rathkopf, M., Ransom, J., Sim, I., Giri, L., Quinn, J., et al., 2005. ICAAC abstract, LB-25."},{"key":"10.1016\/j.vaccine.2009.10.094_bib22","doi-asserted-by":"crossref","first-page":"5785","DOI":"10.4049\/jimmunol.181.8.5785","article-title":"Effect of CpG oligonucleotides on vaccine-induced B cell memory","volume":"181","author":"Tross","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2009.10.094_bib23","article-title":"Inductive and suppressive networks regulate TLR9-dependent gene expression in vivo","author":"Klaschik","year":"2008","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.vaccine.2009.10.094_bib24","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.molimm.2006.07.283","article-title":"CpG-mediated changes in gene expression in murine spleen cells identified by microarray analysis","volume":"44","author":"Klaschik","year":"2007","journal-title":"Mol Immunol"},{"key":"10.1016\/j.vaccine.2009.10.094_bib25","doi-asserted-by":"crossref","first-page":"4463","DOI":"10.4049\/jimmunol.161.9.4463","article-title":"CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice","volume":"161","author":"McCluskie","year":"1998","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2009.10.094_bib26","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.4049\/jimmunol.157.5.2116","article-title":"Macrophages ingest and are activated by bacterial DNA","volume":"157","author":"Stacey","year":"1996","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2009.10.094_bib27","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2165\/00063030-199810050-00001","article-title":"The CpG motif: implications for clinical immunology","volume":"10","author":"Krieg","year":"1998","journal-title":"BioDrugs"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X09016430?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X09016430?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T17:02:31Z","timestamp":1685466151000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X09016430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2010,2]]}},"alternative-id":["S0264410X09016430"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2009.10.094","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2010,2]]}}}